A Phase 3 interventional study of somatropin and somatropin in Genetic Disorder and Noonan Syndrome, sponsored by Novo Nordisk A/S. Completed at 1 site in Sweden. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-01-18.
Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies in Genetic Diseases, Inborn by Novo Nordisk A/S — none open to participants now, 2 under way, 2 of them phase 3. Genetic Diseases, Inborn · Novo Nordisk A/S.
Among the 23 studies in Genetic Diseases, Inborn by Novo Nordisk A/S, this one is the 14th largest by enrollment of the 15 interventional ones that give a count, is the only one that started in 1990, is one of 8 in phase 3, and was the 7th registered.
584 studies on the registry are indexed under Genetic Diseases, Inborn; 158 are open to participants now.
Browse Genetic Diseases, Inborn studies →None of the 23 studies in Genetic Diseases, Inborn by Novo Nordisk A/S is open now. The open studies under Genetic Diseases, Inborn, anywhere →
Of the 121 Genetic Diseases, Inborn studies recruiting now, 60 (50%) set no upper age limit and 46 (38%) stop at 75 or younger; 86 take children under 18; 28 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
First in 1987; this study’s year is marked. 1 started in 1990.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 24 is below the median of 41 across 306 interventional studies indexed under Genetic Diseases, Inborn.
Median enrollment 51 across the 15 interventional studies, 238 across the 8 observational. Of the 21 that completed or were terminated, 3 (14%) have results posted.
This tab as a report to print or save as PDF → With an account.
Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 23 studies in Genetic Diseases, Inborn by Novo Nordisk A/S, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This trial is conducted in Europe. The aim of this trial is to evaluate the effect of somatropin (Norditropin®) on final height in children with Noonan syndrome having being treated for up to 10 years with somatropin (Norditropin®) for the attainment of an optimal final height in the original trial S/GHD/004/NOO.
Inclusion Criteria:
Drug: somatropin
Drug: somatropin
Retrospective data collection based on data obtained from a prospective, open-label, randomised, parallel-group trial (S/GHD/004/NOO) combined with a present follow-up visit
Retrospective data collection based on data obtained from a prospective, open-label, randomised, parallel-group trial (S/GHD/004/NOO) combined with a present follow-up visit
Change in height SDS (Standard Deviation Score) from start of treatment to final height (referenced to normal population)
Final height SDS
Change in height SDS from start of treatment to final height (referenced to Noonan population)
Height velocity
Change in height velocity
Sitting height
Number and proportion of subjects with final height SDS above -2 SDS
Adverse events
The record gives a start of Jun 1990, a primary completion of Sep 2005 and a completion of Sep 2005. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Human Growth Hormone